Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Free Cash Flow: 2021-2025

Historic Free Cash Flow for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$14.3 million.

  • ProQR Therapeutics N.V's Free Cash Flow fell 130.23% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$56.7 million, marking a year-over-year decrease of 61.41%. This contributed to the annual value of -$43.3 million for FY2024, which is 298.23% down from last year.
  • According to the latest figures from Q3 2025, ProQR Therapeutics N.V's Free Cash Flow is -$14.3 million, which was down 10.83% from -$12.9 million recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics N.V's Free Cash Flow registered a high of $48.7 million during Q2 2023, and its lowest value of -$23.0 million during Q1 2022.
  • Its 3-year average for Free Cash Flow is -$5.1 million, with a median of -$10.5 million in 2023.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 520.19% in 2022, then soared by 407.47% in 2023.
  • Over the past 5 years, ProQR Therapeutics N.V's Free Cash Flow (Quarterly) stood at $4.3 million in 2021, then slumped by 520.19% to -$18.2 million in 2022, then skyrocketed by 68.53% to -$5.7 million in 2023, then crashed by 124.43% to -$12.9 million in 2024, then plummeted by 130.23% to -$14.3 million in 2025.
  • Its last three reported values are -$14.3 million in Q3 2025, -$12.9 million for Q2 2025, and -$16.6 million during Q1 2025.